Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Free Cash Flow (2021 - 2025)

Amylyx Pharmaceuticals has reported Free Cash Flow over the past 5 years, most recently at -$28.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$28.0 million for Q4 2025, up 52.58% from a year ago — trailing twelve months through Dec 2025 was -$123.5 million (up 26.41% YoY), and the annual figure for FY2025 was -$123.5 million, up 26.41%.
  • Free Cash Flow for Q4 2025 was -$28.0 million at Amylyx Pharmaceuticals, up from -$30.4 million in the prior quarter.
  • Over the last five years, Free Cash Flow for AMLX hit a ceiling of $13.2 million in Q4 2023 and a floor of -$66.7 million in Q2 2024.
  • Median Free Cash Flow over the past 5 years was -$28.2 million (2021), compared with a mean of -$26.9 million.
  • Biggest five-year swings in Free Cash Flow: surged 126.22% in 2023 and later plummeted 7064.57% in 2025.
  • Amylyx Pharmaceuticals' Free Cash Flow stood at -$28.4 million in 2021, then tumbled by 76.99% to -$50.3 million in 2022, then surged by 126.22% to $13.2 million in 2023, then tumbled by 547.35% to -$59.0 million in 2024, then surged by 52.58% to -$28.0 million in 2025.
  • The last three reported values for Free Cash Flow were -$28.0 million (Q4 2025), -$30.4 million (Q3 2025), and -$25.3 million (Q2 2025) per Business Quant data.